Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases

被引：47

作者：

Guan, Shi-Yang ^{[1
,2
]}

Leng, Rui-Xue ^{[1
,2
]}

Khan, Muhammad Imran ^{[1
,2
]}

Qureshi, Humera ^{[1
,2
]}

Li, Xiang-Pei ^{[3
]}

Ye, Dong-Qing ^{[1
,2
]}

Pan, Hai-Feng ^{[1
,2
]}

机构：

[1] Anhui Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, 81 Meishan Rd, Hefei 230032, Anhui, Peoples R China

[2] Anhui Med Univ, Anhui Prov Lab Populat Hlth & Major Dis Screening, 81 Meishan Rd, Hefei, Anhui, Peoples R China

[3] Anhui Prov Hosp, Dept Rheumatol & Immunol, 17 Lujiang Rd, Hefei, Anhui, Peoples R China

来源：

INFLAMMATION | 2017年 / 40卷 / 01期

基金：

中国国家自然科学基金;

关键词：

interleukin-35; Th17; cells; Treg cells; therapeutic agent; autoimmune diseases; REGULATORY T-CELLS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; MESENCHYMAL STEM-CELLS; B-CELLS; TH17/TREG IMBALANCE; INDUCED ARTHRITIS; IMMUNE-RESPONSES; MURINE MODEL; IL-35; CYTOKINE;

D O I：

10.1007/s10753-016-0453-9

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Autoimmune diseases contain a large number of pathologies characterized by various factors that contribute to a breakdown in self-tolerance. Cytokine-mediated immunity plays an essential role in the pathogenesis of varieties of autoimmune diseases. Recent studies reveal that interleukin-35 (IL-35), a newly identified cytokine of IL-12 family, is implicated in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), etc. In this review, we will discuss the biological features of IL-35 and summarize recent advances in the role of IL-35 in the development and pathogenesis of autoimmune diseases; the discoveries gained from these findings might translate into future therapies for these diseases.

引用

页码：303 / 310

页数：8

共 50 条

[31] Interleukin-35: Expanding Its Job Profile
Sawant, Deepali V.
Hamilton, Kristia
Vignali, Dario A. A.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2015, 35 (07): : 499 - 512
[32] Pathogenesis and Function of Interleukin-35 in Rheumatoid Arthritis
Xin, Pan Lin
Jie, Li Fan
Cheng, Qian
Bin, Du Yi
Dan, Cheng Wen
FRONTIERS IN PHARMACOLOGY, 2021, 12
[33] Molecular Pathways: Interleukin-35 in Autoimmunity and Cancer
Pylayeva-Gupta, Yuliya
CLINICAL CANCER RESEARCH, 2016, 22 (20) : 4973 - 4978
[34] Therapeutic Window of Interleukin-2 for Autoimmune Diseases
Tang, Qizhi
DIABETES, 2015, 64 (06) : 1912 - 1913
[35] Therapeutic potential of phages in autoimmune liver diseases
Gorski, A.
Jonczyk-Matysiak, E.
Lusiak-Szelachowska, M.
Weber-Dabrowska, B.
Miedzybrodzki, R.
Borysowski, J.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2018, 192 (01): : 1 - 6
[36] Expression of Interleukin-35 in Children with Acute Allergic Asthma
Cai, Zhangqiao
He, Yuxia
Yang, Jing
IRANIAN JOURNAL OF IMMUNOLOGY, 2021, 18 (03) : 195 - 202
[37] Different expression levels of interleukin-35 in asthma phenotypes
Li, Wei
Gao, Ruihan
Xin, Tong
Gao, Peng
RESPIRATORY RESEARCH, 2020, 21 (01)
[38] Interleukin-35: odd one out or part of the family?
Collison, Lauren W.
Vignali, Dario A. A.
IMMUNOLOGICAL REVIEWS, 2008, 226 : 248 - 262
[39] Interleukin-35 is associated with the tumorigenesis and progression of prostate cancer
Zhu, Jialin
Yang, Xueling
Wang, Yan
Zhang, Haonan
Guo, Zhi
ONCOLOGY LETTERS, 2019, 17 (06) : 5094 - 5102
[40] Interleukin-35: A Serological Biomarker for Patients with Polymyositis/Dermatomyositis
Jiang, Qinglai
Li, Yuxuan
Xia, Liping
Shen, Hui
Lu, Jing
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2019, 39 (11): : 720 - 725

← 1 2 3 4 5 →